Inicio
Proyectos y Estudios
Evaluación de la eficacia y de la seguridad de avapritnib en vida real en una serie de casos diagnosticados de tumor del estroma gastrointestinal (TEGI), con mutación PDGFRA D842V con enfermedad localmente avanzada o metastásica, tratados con avapritinib en cualquier línea de tratamiento.

Evaluación de la eficacia y de la seguridad de avapritnib en vida real en una serie de casos diagnosticados de tumor del estroma gastrointestinal (TEGI), con mutación PDGFRA D842V con enfermedad localmente avanzada o metastásica, tratados con avapritinib en cualquier línea de tratamiento.

Datos básicos

Protocolo:: AVARWE
EUDRACT:
NCT:
Centro:: HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
Año de incio:: 2023
Año de finalización:

ESTUDIO OBSERVACIONAL

Documentos

No hay documentos

Participantes

Roberto Pedro Díaz Beveridge

Investigador Principal
Maite Giralt Ferrer

Data Manager / Study Coordinator

Grupos

Investigación Clínica y Traslacional en Cáncer

Leader

José Gómez Codina

Financiadores - Promotores

FUNDACIO PRIVADA INSTITUT D´INVESTIGACIÓ ONCOLOGICA DE VALL-HEBRON (VHIO)

Resultados del Ensayo Clínico

Publicaciones en Revistas 11

Encorafenib (E) plus binimetinib (B) in unresectable advanced or metastatic BRAFV600-mut melanoma, real-world evidence in Spain (GEM 2002-BECARE)

Soria, A.; (...); Cerezuela-Fuentes, P.

Meeting Abstract. 10.1016/j.annonc.2023.09.2248. 2023

Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study).

Marquez-Rodas, Ivan; (...); Berrocal, Alfonso

Article. 10.1093/neuonc/noae116. 2024

First in human trial of CEB-01 for retroperitoneal soft tissue sarcoma

Gonzalez, J. A.; (...); Lopez Pousa, A.

Meeting Abstract. 10.1016/j.annonc.2023.09.1161. 2023

First-in-human CEB-01: Novel loco-regional SN-38 release membrane to prevent local recurrence in retroperitoneal sarcomas

Gonzalez-Lopez, Jose Antonio; (...); Pousa, Antonio Lopez

Meeting Abstract. https://doi.org/10.1016/j.annonc.2023.09.1161. 2024

Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG).

Gronchi, Alessandro; (...); Casali, Paolo Giovanni

Article. 10.1200/JCO.23.00908. 2024

Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol

Salazar, Juliana; (...); Sebio, Ana

Article. 10.3390/pharmaceutics16121585. 2024

Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS).

Martin-Broto J; (...); Hindi N

Article. 10.1200/JCO.24.00358. 2024

Real-world effectiveness and safety of second- or third-line pegylated liposomal irinotecan plus 5-fluorouracil and folinic acid in pancreatic ductal adenocarcinoma in Spain

Alvarez-Gallego, Rafael; (...); Cubillo, Antonio

Article. 10.1177/17588359241309828. 2025

Redefining radiologic responses (RR) in solid tumors: Shall we brace ourselves for a post-RECIST era? Results from a randomized clinical trial (RCT) on neoadjuvant chemotherapy in high-risk soft-tissue sarcomas (HR-STS) of the trunk or extremities

Vanzulli, Andrea; (...); Gronchi, Alessandro

Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.11553. 2024

Redefining radiologic responses in high-risk soft-tissue sarcomas treated with neoadjuvant chemotherapy: final results of ISG-STS 1001, a randomized clinical trial.

Vanzulli, A; (...); Gronchi, A

Article. 10.1016/j.esmoop.2025.104299. 2025

Spatial distribution of tumour immune infiltrate predicts outcomes of patients with high-risk soft tissue sarcomas after neoadjuvant chemotherapy.

Pasquali, Sandro; (...); Gronchi, Alessandro

Article. 10.1016/j.ebiom.2024.105220. 2024